IRB #
STUDY00022395
Title
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, Estrogen Receptor Positive, HER2-negative Breast Cancer (DARE)
Principal Investigator
Alexandra Zimmer
Study Purpose
The purpose of this research is to find out if detecting cancer-related abnormal DNA molecules in your blood, called circulating tumor DNA, or ctDNA, can predict a subsequent clinical recurrence of the cancer, and if starting a new treatment when we first detect ctDNA in your blood could prevent, or delay, the clinical recurrence of the cancer.
Medical Condition(s)
High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Eligibility Criteria
Have Stage II or II, HER2-negavie, ER-positive invasive breast cancer
Currently receiving endocrine therapy and have completed at least 6 months, but no more than 7 years
Clinical and pathological high risk for recurrence
Age Range
18 - 101
Healthy Volunteers Needed
No
Duration of Participation
Your participation in this study could last up to 7 years.
Minors Included
No
Contact
Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080
Sponsor
CRITERIUM Inc. doing business as Academic Breast Cancer Consortium (ABRCC) with support from Pfizer Pharmaceuticals
Recruitment End
12/31/2030
Compensation Provided
No
Go Back